Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group

References

• Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut + AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–1857.
   PubMed Web of Science ®Google Scholar
• Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97(3):388–392.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;2022:1200–1228.
   Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar
• Oñate G, Bataller A, Garrido A, et al. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882–890.
   PubMed Web of Science ®Google Scholar
• Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116(7):1132–1135.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2011;29(10):1373–1381.
   PubMed Web of Science ®Google Scholar
• Werstein B, Dunlap J, Cascio MJ, et al. Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival. J Mol Diagn. 2020;22(3):338–345.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340–350.
   PubMed Web of Science ®Google Scholar
• Li Z, Stölzel F, Onel K, et al. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015;29(10):2113–2116.
   PubMed Web of Science ®Google Scholar
• Begna KH, Kittur J, Yui J, et al. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol. 2021;195(3):413–416.
   PubMed Web of Science ®Google Scholar
• Greenland NY, van Ziffle JA, Liu YC, et al. Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia. Hum Pathol. 2021;108:76–83.
   PubMed Web of Science ®Google Scholar
• Movassaghian M, Brunner AM, Blonquist TM, et al. Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma. 2015;56(6):1698–1703.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Wen S, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008;113(6):1370–1378.
   PubMed Web of Science ®Google Scholar
• Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol. 2003;25(10):760–768.
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer. 2002;94(6):1739–1746.
   PubMed Web of Science ®Google Scholar
• Falini B, Lenze D, Hasserjian R, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21(7):1566–1570.
   PubMed Web of Science ®Google Scholar
• Alexiev BA, Wang W, Ning Y, et al. Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study. Diagn Pathol. 2007;2(1):42.
   PubMedGoogle Scholar
• Anekpuritanang T, Klairmont MM, Gradowski J, et al. In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. Blood Adv. 2021;5(23):5057–5059.
   PubMed Web of Science ®Google Scholar
• Halahleh K, Alhalaseh Y, Al-Rimawi D, et al. Extramedullary acute myeloid leukemia (eAML): retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes. Ann Med Surg. 2021;72:102894.
   PubMed Web of Science ®Google Scholar
• Willekens C, Renneville A, Broutin S, et al. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia. 2018;32(9):2008–2081.
   PubMed Web of Science ®Google Scholar
• Ullman DI, Dorn D, Jones JA, et al. Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia. Histopathology. 2019;75(2):185–192.
   PubMed Web of Science ®Google Scholar
• Claerhout H, Van Aelst S, Melis C, et al. Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study. Eur J Haematol. 2018;100(6):603–612.
   PubMed Web of Science ®Google Scholar
• Kaur V, Swami A, Alapat D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018;23(1):17–24.
   PubMed Web of Science ®Google Scholar
• Eckardt JN, Stölzel F, Kunadt D, et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol. 2022;15(1):1–13.
   PubMed Web of Science ®Google Scholar
• Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48:1426–1437.
   Google Scholar
• Stölzel F, Lüer T, Löck S, et al. The prevalence of extramedullary acute myeloid leukemia detected by 18 FDG-PET/CT: final results from the prospective PETAML trial. Haematologica. 2020;105(6):1552–1558.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Patel SS, Kuo FC, Gibson CJ, et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816–2825.
   PubMed Web of Science ®Google Scholar
• Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049–1059.
   PubMed Web of Science ®Google Scholar
• Ramia de Cap M, Kaul S. Limitations of multivariate survival analysis. Mod Pathol. 2021;35:993.
   PubMed Web of Science ®Google Scholar